Economic Impact of Palifermin on the Costs of Hospitalization for Autologous Hematopoietic Stem-Cell Transplant: Analysis of Phase 3 Trial Results

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 7, 2007, Pages 806-813

  Elting, Linda S ^a   Shih, Ya Chen Tina ^a   Stiff, Patrick J ^b   Bensinger, William ^c   Cantor, Scott B ^a   Cooksley, Catherine ^a   Spielberger, Ricardo ^d   Emmanoulides, Christos ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e INTERBALKAN MEDICAL CENTER   (Greece)

Author keywords

Cancer; Cost of illness; Economic analysis; Palifermin; Stem cell transplant

Indexed keywords

ANTINEOPLASTIC AGENT; PALIFERMIN; PLACEBO;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FUNGEMIA; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION COST; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MUCOSA INFLAMMATION; PNEUMONIA; RETROSPECTIVE STUDY; TOTAL PARENTERAL NUTRITION; UNITED STATES; WHOLE BODY RADIATION;

ADULT; CLINICAL TRIALS, PHASE III AS TOPIC; COSTS AND COST ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTOR 7; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMANS; MALE; MEDICARE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMATITIS; TRANSPLANTATION, AUTOLOGOUS; UNITED STATES; WHOLE-BODY IRRADIATION;

EID: 34250207691     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.03.004     Document Type: Article

References (22)

1. Filicko J., Lazarus H.M., and Flomenberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant 31 (2003) 1-10
2. Sonis S.T., Oster G., Fuchs H., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19 (2001) 2201-2205
3. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6 (1988) 1562-1568
4. McGuire D.B., Altomonte V., Peterson D.E., et al. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 20 (1993) 1493-1502
5. Pico J.L., Avila-Garavito A., and Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3 (1998) 446-451
6. Woo S.B., Sonis S.T., Monopoli M.M., and Sonis A.L. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72 (1993) 1612-1617
7. Elting L.S., Cooksley C., Chambers M., et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98 (2003) 1531-1539
8. Spielberger R., Stiff P., Bensinger W., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 (2004) 2590-2598
9. Emmanoulides C., Spielberger R., Stiff P., et al. Paliferm treatment of mucositis in transplant patients reduces health resource use: Phase 3 results. Abstracts of the American Society of Hematology 45th Annual Meeting. December 6-9, 2003. San Diego, CA. Blood 102 (2003) Abstract 883
10. Horsley P., Bauer J.D., Mazkowiack R., Gardner R., and Bashford J. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 15 (2007) 105-109
11. Schoenman J.A., Sutton J.P., Kintala S., Love D., and Maw R. The Value of Hospital Discharge Databes (2005), NORC at the University of Chicago, National Association of Health Data Organizations, Chicago, IL 1-102
12. Statewide average operating cost-to-charge ratios for urban and rural hospitals Federal Register Vol 67, No.148. Thursday, August 1, 2002/Rules and Regulations, p. 50263.
13. Bureau of Labor Statistics. Consumer Price Index-All Urban Consumers Accessed on Jan 20, 2006 from http://data/bls/gov/cgi-bin/surveymost
14. Centers for Medicare and Medicaid Services. Medicare Part B Drug Average Sales Price. January 2006. Accessed on February 2, 2006 from http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/02_aspfiles.asp#TopOfPage
15. Sonis S.T. Pathobiology of mucositis. Semin Oncol Nurse 20 (2004) 11-15
16. Ruescher T.J., Sodeifi A., Scrivani S.J., Kaban L.B., and Sonis S.T. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82 (1998) 2275-2281
17. Sonis S.T., Elting L.S., Keefe D., et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 (2004) 1995-2025
18. Rubenstein E.B., Peterson D.E., Schubert M., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 (2004) 2026-2046
19. Stiff P.J. Oral mucositis therapy comes of age. J Support Oncol 3 (2005) 73-75
20. Stiff P.J., Emmanouilides C., Bensinger W.I., et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 24 (2006) 5185-5193
21. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
22. Karnofsy D.A., and Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C.M. (Ed). Evaluation of Chemotherapeutic Agents (1949), Columbia University Press, New York 196